PsyBio Therapeutics Retains KCSA Strategic Communications for Investor Relations Services

TORONTO, April 9, 2021 /CNW/ -- PsyBio Therapeutics Corp. (TSXV: PSYB) ("PsyBio" or the "Company"), a biotechnology company pioneering the next generation of targeted psychoactive medications, announces that it has entered into an investor relations agreement (the "Agreement") with Kanan Corbin Schupak & Aronow, Inc. d/b/a KCSA Strategic Communications ("KCSA") to provide investor relations services (the "Services").

PsyBio has selected KCSA to enhance its visibility and profile in the financial community, as the Company continues to execute on its strategies. Pursuant to the engagement, and subject to the overall direction of the Company, KCSA will provide assistance in better engaging with current and potential investors of PsyBio and will work closely with the Company to develop and deploy a comprehensive capital markets strategy. Activities will include providing an investor relations program catering to the financial community, shareholders, and investors.

The provision of the Services are expected to commence on April 9, 2021 for an initial term of six months. The Agreement can be terminated at any time thereafter by the Company or KCSA by providing 30 days' written notice to the other party of such termination.

Pursuant to the Agreement, KCSA will be paid a monthly fee of US$8,500 as consideration for the provision of the Services. KCSA will not receive any securities as compensation. The Company and KCSA act at arm's length and KCSA does not currently own any securities of PsyBio, however, KCSA and its clients may acquire a direct interest in the securities of the Company.

The engagement of KCSA remains subject to the approval of the TSX Venture Exchange.

About PsyBio Therapeutics Corp.

PsyBio is a biotechnology company developing novel formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health and other disorders. The team has experience in drug discovery based on synthetic biology as well as clinical and regulatory experience moving drugs through human studies and regulatory protocols. Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of halucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof. The Company is also researching and developing new non-naturally occurring molecular structures which may have unique therapeutics properties.

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that constitute "forward-looking information" ("forward-looking information") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forwardlooking information and are based on expectations, estimates and projections as at the date of this news release. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. In disclosing the forward-looking information contained in this press release, the Company has made certain assumptions, including that: PsyBio will be successful in protecting its intellectual property and filing new patent applications within the next year; PsyBio will be successful in discovering new valuable target molecules; PsyBio will be successful in obtaining Investigation New Drug Applications and will be able to obtain all necessary approvals for clinical trials; PsyBio's technology will be safe and effective; and that drug development involves long lead times, is very expensive and involves many variables of uncertainty. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, it can give no assurance that the expectations of any forward-looking information will prove to be correct. Known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forwardlooking information. Such factors include, but are not limited to: compliance with extensive government regulations; domestic and foreign laws and regulations adversely affecting PsyBio's business and results of operations; decreases in the prevailing process for psilocybin and nutraceutical products in the markets in which PsyBio operates; the impact of COVID-19; and general business, economic, competitive, political and social uncertainties. Accordingly, readers should not place undue reliance on the forwardlooking information contained in this press release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking information to reflect actual results, whether as a result of new information, future events, changes in assumptions, changes in factors affecting such forward-looking information or otherwise.

PsyBio makes no medical, treatment or health benefit claims about PsyBio's proposed products. The U.S. Food and Drug Administration (the "FDA") or other similar regulatory authorities have not evaluated claims regarding psilocybin and other next generation psychoactive compounds. The efficacy of such products have not been confirmed by FDA-approved research. There is no assurance that the use of psilocybin and other psychoactive compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. PsyBio has not conducted clinical trials for the use of its intellectual property. Any references to quality, consistency, efficacy and safety of potential products do not imply that PsyBio verified such in clinical trials or that PsyBio will complete such trials. If PsyBio cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on the PsyBio's performance and operations.

The TSX Venture Exchange (the "TSXV") has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

SOURCE PsyBio Therapeutics Corp.

For further information contact: Evan Levine, CEO, PsyBio Therapeutics Corp., t: 226.286.0348, e: [email protected]; Media Enquiries: Kirsten Frazer, PhD, LifeSci Communications, t: 646.863.0222, e: [email protected]